Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (10): 1020-1024.doi: 10.11958/20240332
• Cell and Molecular Biology • Previous Articles Next Articles
QIAO Na(), TIAN Ying, CHEN Yang, HAO Jing
Received:
2024-03-18
Revised:
2024-04-26
Published:
2024-10-15
Online:
2024-10-14
QIAO Na, TIAN Ying, CHEN Yang, HAO Jing. Impacts of lncRNA MALAT1 on apoptosis, autophagy of granulosa cells and PI3K/Akt/mTOR pathway in polycystic ovary syndrome[J]. Tianjin Medical Journal, 2024, 52(10): 1020-1024.
CLC Number:
组别 | OD450 | ||||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
control组 | 0.31±0.03 | 0.47±0.05 | 0.72±0.08 | ||
si-NC组 | 0.34±0.03 | 0.44±0.04 | 0.68±0.06 | ||
si-MALAT1组 | 0.18±0.02ab | 0.31±0.02ab | 0.45±0.05ab | ||
pc-NC组 | 0.29±0.03 | 0.48±0.04 | 0.67±0.07 | ||
pc-MALAT1组 | 0.45±0.04c | 0.66±0.07c | 0.91±0.08c | ||
pc-MALAT1+740Y-P组 | 0.26±0.03d | 0.38±0.04d | 0.62±0.06d | ||
F | 51.621** | 39.848** | 29.155** | ||
组别 | MALAT1 mRNA | 凋亡率/% | |||
control组 | 1.07±0.09 | 16.41±1.76 | |||
si-NC组 | 1.04±0.08 | 18.24±2.35 | |||
si-MALAT1组 | 0.43±0.04ab | 40.67±3.58ab | |||
pc-NC组 | 1.12±0.10 | 16.84±1.62 | |||
pc-MALAT1组 | 1.86±0.23c | 8.27±0.84c | |||
pc-MALAT1+740Y-P组 | 1.82±0.21 | 21.52±1.83d | |||
F | 85.308** | 151.729** |
Tab.1 Comparison of the OD450 value, MALAT1 mRNA expression level and apoptosis rate of KGN cells between six groups
组别 | OD450 | ||||
---|---|---|---|---|---|
24 h | 48 h | 72 h | |||
control组 | 0.31±0.03 | 0.47±0.05 | 0.72±0.08 | ||
si-NC组 | 0.34±0.03 | 0.44±0.04 | 0.68±0.06 | ||
si-MALAT1组 | 0.18±0.02ab | 0.31±0.02ab | 0.45±0.05ab | ||
pc-NC组 | 0.29±0.03 | 0.48±0.04 | 0.67±0.07 | ||
pc-MALAT1组 | 0.45±0.04c | 0.66±0.07c | 0.91±0.08c | ||
pc-MALAT1+740Y-P组 | 0.26±0.03d | 0.38±0.04d | 0.62±0.06d | ||
F | 51.621** | 39.848** | 29.155** | ||
组别 | MALAT1 mRNA | 凋亡率/% | |||
control组 | 1.07±0.09 | 16.41±1.76 | |||
si-NC组 | 1.04±0.08 | 18.24±2.35 | |||
si-MALAT1组 | 0.43±0.04ab | 40.67±3.58ab | |||
pc-NC组 | 1.12±0.10 | 16.84±1.62 | |||
pc-MALAT1组 | 1.86±0.23c | 8.27±0.84c | |||
pc-MALAT1+740Y-P组 | 1.82±0.21 | 21.52±1.83d | |||
F | 85.308** | 151.729** |
组别 | Bcl-2 | Bax | LC3Ⅱ/ LC3Ⅰ | Beclin1 |
---|---|---|---|---|
control组 | 0.67±0.06 | 0.32±0.02 | 0.56±0.04 | 0.47±0.05 |
si-NC组 | 0.65±0.07 | 0.29±0.02 | 0.58±0.03 | 0.43±0.05 |
si-MALAT1组 | 0.31±0.04ab | 0.74±0.07ab | 1.17±0.13ab | 0.86±0.07ab |
pc-NC组 | 0.64±0.06 | 0.33±0.03 | 0.59±0.03 | 0.48±0.05 |
pc-MALAT1组 | 0.92±0.08c | 0.14±0.02c | 0.27±0.03c | 0.24±0.02c |
pc-MALAT1+ 740Y-P组 | 0.57±0.06d | 0.38±0.03d | 0.69±0.06d | 0.57±0.06d |
F | 58.370** | 182.582** | 125.632** | 91.266** |
Tab.2 Comparison of apoptosis and autophagy related proteins in KGN cells between six groups
组别 | Bcl-2 | Bax | LC3Ⅱ/ LC3Ⅰ | Beclin1 |
---|---|---|---|---|
control组 | 0.67±0.06 | 0.32±0.02 | 0.56±0.04 | 0.47±0.05 |
si-NC组 | 0.65±0.07 | 0.29±0.02 | 0.58±0.03 | 0.43±0.05 |
si-MALAT1组 | 0.31±0.04ab | 0.74±0.07ab | 1.17±0.13ab | 0.86±0.07ab |
pc-NC组 | 0.64±0.06 | 0.33±0.03 | 0.59±0.03 | 0.48±0.05 |
pc-MALAT1组 | 0.92±0.08c | 0.14±0.02c | 0.27±0.03c | 0.24±0.02c |
pc-MALAT1+ 740Y-P组 | 0.57±0.06d | 0.38±0.03d | 0.69±0.06d | 0.57±0.06d |
F | 58.370** | 182.582** | 125.632** | 91.266** |
组别 | p-PI3K/PI3K | p-Akt/Akt | p-mTOR/mTOR |
---|---|---|---|
control组 | 0.71±0.07 | 1.14±0.11 | 0.94±0.08 |
si-NC组 | 0.74±0.06 | 1.12±0.09 | 0.98±0.07 |
si-MALAT1组 | 1.18±0.12ab | 1.67±0.28ab | 1.47±0.16ab |
pc-NC组 | 0.76±0.07 | 1.09±0.10 | 1.01±0.10 |
pc-MALAT1组 | 0.35±0.04c | 0.72±0.06c | 0.68±0.06c |
pc-MALAT1+ 740Y-P组 | 0.82±0.07d | 1.26±0.15d | 1.07±0.08d |
F | 73.680** | 25.140** | 41.574** |
Tab.3 Comparison of PI3K/Akt/mTOR path-related proteins in KGN cells between six groups
组别 | p-PI3K/PI3K | p-Akt/Akt | p-mTOR/mTOR |
---|---|---|---|
control组 | 0.71±0.07 | 1.14±0.11 | 0.94±0.08 |
si-NC组 | 0.74±0.06 | 1.12±0.09 | 0.98±0.07 |
si-MALAT1组 | 1.18±0.12ab | 1.67±0.28ab | 1.47±0.16ab |
pc-NC组 | 0.76±0.07 | 1.09±0.10 | 1.01±0.10 |
pc-MALAT1组 | 0.35±0.04c | 0.72±0.06c | 0.68±0.06c |
pc-MALAT1+ 740Y-P组 | 0.82±0.07d | 1.26±0.15d | 1.07±0.08d |
F | 73.680** | 25.140** | 41.574** |
[1] | 韦奕, 张淑芬, 黄梦颖, 等. 青蒿琥酯对多囊卵巢综合征模型大鼠卵巢组织形态的影响[J]. 天津医药, 2022, 50(6):588-594. |
WEI Y, ZHANG S F, HUANG M Y, et al. Effect of artesunate on ovarian tissue morphology in polycystic ovary syndrome model rats[J]. Tianjin Med J, 2022, 50(6):588-594. doi:10.11958/20212673. | |
[2] | AL WATTAR B H, FISHER M, BEVINGTON L, et al. Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome:a systematic review and quality assessment study[J]. J Clin Endocrinol Metab, 2021, 106(8):2436-2446. doi:10.1210/clinem/dgab232. |
[3] | CHEN Y, CHEN Y, CUI X, et al. Down-regulation of MALAT1 aggravates polycystic ovary syndrome by regulating MiR-302d-3p-mediated leukemia inhibitory factor activity[J]. Life Sci, 2021, 277:119076. doi:10.1016/j.lfs.2021.119076. |
[4] | ELMONIER A A, EL-BOGHDADY N A, FAHIM S A, et al. LncRNA NEAT1 and MALAT1 are involved in polycystic ovary syndrome pathogenesis by functioning as competing endogenous RNAs to control the expression of PCOS-related target genes[J]. Noncoding RNA Res, 2023, 8(2):263-271. doi:10.1016/j.ncrna.2023.02.008. |
[5] | 郭向东, 王青玲, 张梦娴, 等. 补肾活血汤通过调控PI3K/Akt/mTOR通路对HEI-OC1细胞的抗衰老作用[J]. 中成药, 2023, 45(3):930-935. |
GUO X D, WANG Q L, ZHANG M X, et al. Anti-aging effect of Bushen Huoxue Decoction on HEI-OC1 cells by regulating PI3K/Akt/mTOR pathway[J]. Chinese Patent Medicine, 2023, 45(3):930-935. doi:10.3969/j.issn.1001-1528.2023.03.041. | |
[6] | CHEN Q, ZHANG H, YANG Y, et al. Metformin attenuates UVA-induced skin photoaging by suppressing mitophagy and the PI3K/AKT/mTOR pathway[J]. Int J Mol Sci, 2022, 23(13):6960. doi:10.3390/ijms23136960. |
[7] | ZHENG J, LIU C, SHI J, et al. AIM2 inhibits the proliferation,invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway[J]. Mol Med Rep, 2022, 25(2):53. doi:10.3892/mmr.2021.12569. |
[8] | GUAN C, ZAHID S, MINHAS A S, et al. Polycystic ovary syndrome:a "risk-enhancing" factor for cardiovascular disease[J]. Fertil Steril, 2022, 117(5):924-935. doi:10.1016/j.fertnstert.2022.03.009. |
[9] | REDDY Y. Pulmonary hypertension in polycystic ovarian syndrome[J]. Arq Bras Cardiol, 2021, 116(4):812-813. doi:10.36660/abc.20210106. |
[10] | SU Y, LIANG C, YANG Q. LncRNA MALAT1 promotes glioma cell growth through sponge miR-613[J]. J BUON, 2021, 26(3):984-991. |
[11] | PENG N, HE J, LI J, et al. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis[J]. Cancer Cell Int, 2020, 20:165. doi:10.1186/s12935-020-01231-w. |
[12] | SHIAU J P, CHUANG Y T, CHENG Y B, et al. Impacts of oxidative stress and PI3K/AKT/mTOR on metabolism and the future direction of investigating fucoidan-modulated metabolism[J]. Antioxidants (Basel), 2022, 11(5):911. doi:10.3390/antiox11050911. |
[13] | SKOLARIKI A, D'COSTA J, LITTLE M, et al. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance:concept to clinic[J]. Explor Target Antitumor Ther, 2022, 3(2):172-199. doi:10.37349/etat.2022.00078. |
[14] | CHEN X, TANG H, LIANG Y, et al. Acupuncture regulates the autophagy of ovarian granulosa cells in polycystic ovarian syndrome ovulation disorder by inhibiting the PI3K/AKT/mTOR pathway through LncMEG3[J]. Biomed Pharmacother, 2021, 144:112288. doi:10.1016/j.biopha.2021.112288. |
[15] | XU B, DAI W, LIU L, et al. Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway[J]. Endocr J, 2022, 69(7):863-875. doi:10.1507/endocrj.EJ21-0480. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||